SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

A breakout to a fresh 52-week high ahead of the anticipated Q3 earnings report is driving attention, with traders focused on BRIUMVIs sales momentum and the possibility of an earnings beat. Buyout and short-squeeze speculation is also prominent, but remains unconfirmed.

Amazon.com, Inc. is a multinational technology company, which engages in the provision of online retail shopping services. It operates through the following segments: North America, International, and Amazon Web Services (AWS). The North America segment offers retail sale of consumer products, including from sellers, advertising, and subscriptions services through North America-focused online and physical stores. The International segment focuses on retail sale of consumer products, including sellers, advertising, and subscription services through internationally focused online stores. The AWS segment is composed of global sales of computers, storage, databases, and other services for start-ups, enterprises, government agencies, and academic institutions. The company was founded by Jeffrey P. Bezos in July 1994 and is headquartered in Seattle, WA.

Amazon.com Inc.

Amazon.com Inc

Amazons quarterly results and heavy AI infrastructure spending drove debate, as investors weighed weaker-than-expected results and sharply negative free cash flow against accelerating AWS growth and its outlook. Traders were split between concerns that cash burn and rising investment could pressure the stock and dip-buyers who viewed the initial selloff as overdone; shares rebounded substantially from their lows.

Agenus, Inc. is a clinical-stage company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. Its product pipeline includes Balstilimab, Zalifrelimab, AGEN1181, AGEN1327, AGEN2373, AGENt-797 and AGEN1777. The company was founded by Garo H. Armen and Pramod K. Srivastava on March 31, 1994 and is headquartered in Lexington, MA.

Agenus Inc

Agenuss BOT+BAL combination drew attention after Phase 2 NEOASIS data at ESMO showed strong pathologic responses in a small dMMR colon cancer cohort, alongside discussion of sarcoma results. Traders called the findings encouraging but debated their significance given the small, early-stage studies and awaited Phase 3 confirmation, while some questioned why the share price weakened despite the data and raised dilution and execution concerns.

United States Natural Gas Fund LP. - United States Natural Gas Fund

United States Natural Gas Fund, LP

UNG is drawing attention as natural gas prices slide amid mild-weather forecasts that point to weaker heating demand, with surplus inventories adding pressure. Traders are split between buying the decline ahead of winter and expecting further weakness if warm conditions persist; colder forecasts or storage data are seen as potential catalysts for a shift.

Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.

Summit Therapeutics Inc

Summit is drawing attention ahead of the November 14 FDA decision on ivonescimab plus chemotherapy for EGFR-mutated lung cancer, with traders weighing the Phase 3 results and recent positive biliary-cancer data against regulatory concerns, including the lack of statistically significant overall-survival results. Bulls see approval potential and broader promise for the drug, while skeptics stress that the decision remains uncertain and could hinge on FDA concerns about the trial population or manufacturing.

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMD is caught in a broader technology and semiconductor selloff after Intels weak outlook heightened concerns about PC demand and chip-sector growth, with traders also scrutinizing AI spending and elevated valuations ahead of AMDs earnings report. The community is split between expecting sympathy selling to reverse because Intels struggles could benefit AMD, and fearing further pressure if AI expectations reset.

Whirlpool Corp. engages in the manufacturing and marketing of home appliances. Its products include home laundry appliances, refrigerators and freezers, cooking appliances, home dishwashers, and room air-conditioning equipment, mixers, and portable household appliances. The firm's brands include Whirlpool, KitchenAid, Maytag, Consul, Brastemp, Amana, Bauknecht, JennAir, and Indesit. It operates through the following geographical segments: Major Domestic Appliances (MDA) North America, Major Domestic Appliances (MDA) Latin America, Small Domestic Appliances (SDA) Global, and Others. The company was founded by Emory Upton, Fred Upton, and Louis C. Upton on November 11, 1911 and is headquartered in Benton Harbor, MI.

Whirlpool Corp.

Whirlpools weak Q1 results, sharply reduced 2026 outlook and dividend suspension have sparked concern about soft appliance demand and financial strain. Traders debate whether the downturn reflects broader economic pressures or years of management problems, with some calling the selloff an overreaction and others warning of further downside and bankruptcy risk.

Pyth Network (PYTH) is a cryptocurrency launched in 2021and operates on the Solana platform. Pyth Network has a current supply of 9,999,981,857.422035 with 7,874,958,864.894765 in circulation. The last known price of Pyth Network is 0.06503621 USD and is up 3.48 over the last 24 hours. It is currently trading on 450 active market(s) with $50,940,939.77 traded over the last 24 hours. More information can be found at https://pyth.network/.

Pyth Network

Traders are focused on Pyths institutional data-feed adoption, including Nasdaq distribution, and the DAOs revenue-funded PYTH accumulation policy; speculation about a teased Pyth Connect announcement is another catalyst in the discussion. Bullish holders see these developments supporting the RWA and oracle narrative, while skeptics point to weak price action and potential token-unlock selling pressure, and the teased announcements substance remains unknown.

Hedera (HBAR) is a cryptocurrency launched in 2017. Hedera has a current supply of 50,000,000,000 with 44,327,155,828.93500734 in circulation. The last known price of Hedera is 0.07221819 USD and is up 4.74 over the last 24 hours. It is currently trading on 465 active market(s) with $92,347,671.42 traded over the last 24 hours. More information can be found at https://www.hedera.com/.

Hedera Hashgraph

HBARs sharp rally and elevated volume are being linked by traders to IBM-related cloud news and Hederas reported connections to NVIDIAs AI safety platform. Enthusiasm over enterprise and AI use cases is tempered by profit-taking and skepticism that the announcements will translate into meaningful adoption or token demand.

Cameco Corp. engages in the provision of uranium. It operates through the following segments: Uranium and Fuel Services. The Uranium segment is involved in the exploration for, mining, milling, purchase, and sale of uranium concentrate. The Fuel Services segment deals with the refining, conversion, and fabrication of uranium concentrate and the purchase and sale of conversion services. The company was founded in 1988 and is headquartered in Saskatoon, Canada.

Cameco Corp.

Camecos Q3 report and narrower production guidance are driving the selloff, with traders criticizing the results as underwhelming and pointing to Cigar Lake operating setbacks. Some see the drop as justified by near-term execution concerns, while others argue rising uranium prices and long-term nuclear demand support the investment thesis.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Can Tenet Healthcare Beat Q3 Earnings on Ambulatory Care Strength?

Can THC deliver a Q3 earnings beat? Ambulatory Care growth and higher revenues per adjusted admission offer support, but hospital volume declines and costs loom.

Down 27.4% in 4 Weeks, Here's Why Prelude Therapeutics (PRLD) Looks Ripe for a Turnaround 

Prelude Therapeutics (PRLD) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Prelude Therapeutics Teams Up With Lilly To Test Experimental Breast Cancer Drug In Phase 1 Trial

Equity

Prelude expects patient enrollment to begin in Q4 2026, starting with monotherapy dose escalation before advancing to combination cohorts.


Wall Street Analysts See a 58.42% Upside in Prelude Therapeutics (PRLD): Can the Stock Really Move This High?

The consensus price target hints at a 58.4% upside potential for Prelude Therapeutics (PRLD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

Gainers

Gossamer Bio (NASDAQ:GOSS) shares moved upwards by 47.2% to $0.29 during Tuesday's pre-market session. The company's market cap stands at $97.4 million.
Prelude Therapeutics (NASDAQ:PRLD) shares movedread more...

Prelude Therapeutics (PRLD) Upgraded to Buy: Here's Why

Prelude Therapeutics (PRLD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Wall Street Analysts Think Prelude Therapeutics (PRLD) Could Surge 33.59%: Read This Before Placing a Bet

The average of price targets set by Wall Street analysts indicates a potential upside of 33.6% in Prelude Therapeutics (PRLD). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Prelude Therapeutics Incorporated (NASDAQ:PRLD) Given Consensus Recommendation of "Hold" by Analysts

Prelude Therapeutics Incorporated (NASDAQ:PRLD - Get Free Report) has earned an average rating of 'Hold' from the five brokerages that are presently covering the stock, Marketbeat.com reports. One...

Prelude Therapeutics (NASDAQ:PRLD) Coverage Initiated by Analysts at D. Boral Capital

D. Boral Capital initiated coverage on shares of Prelude Therapeutics in a research note on Monday. They set a 'buy' rating and a $9.00 price target on the stock...

Prelude Therapeutics (NASDAQ:PRLD) Rating Increased to Hold at Zacks Research

Zacks Research raised Prelude Therapeutics to a "hold" rating in a research report on Tuesday...

Prelude Therapeutics, Inc. is a clinical-stage oncology company, which engages in the development of novel precision cancer medicines. It also focuses on the design and development of small molecule agents for cancer medicines. The company was founded by Krishna Vaddi in 2016 and is headquartered in Wilmington, DE.

Prelude Therapeutics Inc

Neutral Sentiment

<ul class="summary-bullets"><li>Under the agreement, Lilly will supply abemaciclib, marketed as Verzenio, and Imlunestrant, marketed as Inluriyo.</li><li>The Phase 1 trial will evaluate combinations of PRT13722, an oral KAT6A selective degrader, with these medicines in patients with hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer.</li><li>The FDA cleared Prelude to proceed with the study under its Investigational New Drug (IND) application.</li></ul>Prelude Therapeutics (PRLD) announced a clinical trial collaboration and supply agreement with Eli Lilly and Company (LLY) on Tuesday to evaluate its experimental breast cancer drug PRT13722 in combination with two Lilly medicines.At the time of writing,&nbsp;<a href="https://stocktwits.com/symbol/PRLD">PRLD shares</a> were down more than 7%, while&nbsp;<a href="https://stocktwits.com/symbol/LLY">LLY shares</a> traded 1.5% lower. The iShares Biotechnology ETF (<a href="https://stocktwits.com/symbol/IBB">IBB</a>) declined over 1.5%.<h2 class="st-heading-2">What Does The Lilly Collaboration Involve?</h2>Under the agreement, Lilly will supply Abemaciclib, marketed as Verzenio, and Imlunestrant, marketed as Inluriyo. The Phase 1 trial will evaluate combinations of PRT13722, an oral KAT6A selective degrader, with these medicines in patients with hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer.The FDA cleared Prelude to proceed with the study under its Investigational New Drug (IND) application. The company expects enrollment to begin in the fourth quarter of 2026, starting with monotherapy dose escalation before advancing to combination cohorts.Sean Brusky, Prelude’s chief business and strategy officer, said: “Our preclinical data demonstrate that selectively degrading KAT6A has the potential to improve upon the efficacy and hematologic toxicity seen with dual KAT6A/B inhibitors.” He added that the approach could enable combination treatments that may advance the standard of care in earlier lines of therapy.<h2 class="st-heading-2">What Has Prelude Reported About PRT13722?</h2>At the&nbsp;American Association for Cancer Research (AACR) 2026 Annual Meeting in April, Prelude presented preclinical data showing that PRT13722 produced durable complete tumor regressions as a monotherapy in HR+/HER2- breast cancer cell-line-derived and patient-derived xenograft models at well-tolerated doses.The company also reported synergy when PRT13722 was combined with endocrine therapies, CDK4/6 inhibitors and PI3K inhibitors across HR+ breast cancer models, including ESR1-mutated and acquired therapy-resistant cancer cells.Prelude said the candidate demonstrated an improved hematological safety profile compared with prifetrastat, a dual KAT6A/B inhibitor, in preclinical testing.&nbsp;<h2 class="st-heading-2">How Retail Views PRLD, LLY</h2>Retail sentiment for both PRLD and LLY on Stocktwits remained in ‘Bearish’ territory over the past 24 hours.One Stocktwits user praised PRLD’s collaborations.<stembedurl>https://stocktwits.com/Bernardbaruch1/message/666375649</stembedurl>PRLD shares have risen more than 48% year to date, while LLY shares have gained more than 8% over the same period.Also read: <a href="https://stocktwits.com/news-articles/markets/equity/robinhood-gets-a-price-target-hike-from-truist-as-wall-street-s-earnings-outlook-improves/cZxBnkORBYg">Robinhood Gets A Price Target Hike From Truist As Wall Street’s Earnings Outlook Improves</a>For updates and corrections, email newsroom@stocktwits.com

Young female scientist working in laboratory (Representative image courtesy of Solskin via Getty Images)

Prelude Therapeutics (PRLD) announced a clinical trial collaboration and supply agreement with Eli Lilly and Company (LLY) on Tuesday to evaluate its experimental breast cancer drug PRT13722 in combination with two Lilly medicines.

iShares Biotechnology ETF

Lilly(Eli) & Co

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$3.88
Prev Close	$4.10
Open	$4.02
Dividend Yield	0.00%
50-Day Moving Average	$4.45
Beta	1.90
Avg. Volume	500,491.14
PE Ratio	-4.93

52-Week High	$6.83
52-Week Low	$1.17
Market Capitalization	$309.64M
EPS (Annual)	-$1.29
Price to Book	2.31
Revenue Per Employee	$153,670.89

Feed

News

Sentiment

Earnings

Fundamentals

Info

PRLD Fundamentals